Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milos D Miljkovic

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal for Immunotherapy of Cancer|April 22, 2021
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodiesSigrid P Dubois, Milos D Miljkovic, Thomas A Fleisher, et al.
Blood Advances|January 14, 2022
Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphomaAnusara Daenthanasanmak, Richard N Bamford, Makoto Yoshioka, et al.
Blood Advances|March 4, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphomaMax J Gordon, Milos D Miljkovic, Paige Milhon, et al.
Haematologica|May 12, 2018
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision makingChristopher Melani, Ranjana Advani, Mark Roschewski, et al.
Blood|August 31, 2019
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockadeDaniel A Rauch, Kevin C Conlon, Murali Janakiram, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 11, 2020
<sup>90</sup>Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's LymphomaKevin C Conlon, Claude Sportes, Martin W Brechbiel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset ExpansionKevin C Conlon, E Lake Potter, Stefania Pittaluga, et al.
Nature Medicine|January 9, 2026
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trialTuan Vu, Hacer Durmus, Michael Rivner, et al.
Nature Biomedical Engineering|November 29, 2025
mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cuesC Andrew Stewart, Shaji Daniel, Elizabeth J Curvino, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal for Immunotherapy of Cancer|April 22, 2021
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodiesSigrid P Dubois, Milos D Miljkovic, Thomas A Fleisher, et al.
Blood Advances|January 14, 2022
Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphomaAnusara Daenthanasanmak, Richard N Bamford, Makoto Yoshioka, et al.
Blood Advances|March 4, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphomaMax J Gordon, Milos D Miljkovic, Paige Milhon, et al.
Haematologica|May 12, 2018
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision makingChristopher Melani, Ranjana Advani, Mark Roschewski, et al.
Blood|August 31, 2019
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockadeDaniel A Rauch, Kevin C Conlon, Murali Janakiram, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 11, 2020
<sup>90</sup>Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's LymphomaKevin C Conlon, Claude Sportes, Martin W Brechbiel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset ExpansionKevin C Conlon, E Lake Potter, Stefania Pittaluga, et al.
Nature Medicine|January 9, 2026
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trialTuan Vu, Hacer Durmus, Michael Rivner, et al.
Nature Biomedical Engineering|November 29, 2025
mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cuesC Andrew Stewart, Shaji Daniel, Elizabeth J Curvino, et al.
Pageof 2